Loading…
Loading…
EQUITY / NASDAQ · XNCM
Telomir Pharmaceuticals, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.27 USD · 7.6271%
Observed: Oct 2, 2026, 11:19 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.18 USD · Volume 76,591
20 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Net income | -1,721,528 USD | -5,069,890 USD | — |
| Total liabilities | 332,424 USD | — | — |
| Total equity | 5,033,480 USD | 481,223 USD | +945.98% |
| Total assets | 5,365,904 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Net incomeIncome statement | -1,721,528 USD | -2,712,475 USD | -990,947 USD | — | -10,413,205 USD | -1,102,294 USD | -8,352,012 USD | -5,069,890 USD |
| Total assetsBalance sheet | 5,365,904 USD | — | — | 7,341,361 USD | 7,341,361 USD | 7,402,117 USD | — | — |
| Total equityBalance sheet | 5,033,480 USD | — | 4,962,226 USD | 5,913,370 USD | 5,913,370 USD | 6,979,310 USD | — | 481,223 USD |
| Total liabilitiesBalance sheet | 332,424 USD | — | — | 1,427,991 USD | 1,427,991 USD | 422,807 USD | — | — |
| Financing cash flowCash flow statement | — | 669,458 USD | — | — | 9,708,727 USD | — | 8,550,008 USD | — |
| Operating cash flowCash flow statement | — | -2,785,842 USD | — | — | -3,688,188 USD | — | -2,486,841 USD | — |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/17/2026 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.